GlassScriptPhysician profile
Escipion Pedroza
NPI 1306807771
$1,653.77
in general payments reported to CMS, 2019-2025
30 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $57.04 · 2022: $431 · 2023: $388 · 2024: $395 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $884 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.91 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $275.90 | 2022-2025 | Jardiance, Mounjaro, Humulin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.54 | 2019-2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $130.57 | 2022-2024 | Gvoke Hypopen, Recorlev |
| Dexcom, INC. | $108.80 | 2022-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $93.22 | 2019-2022 | |
| Ibsa Pharma INC. | $81.14 | 2019-2024 | Licart, Tirosint |
| Astrazeneca Pharmaceuticals LP | $80.42 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.53 | 2022-2023 | |
| Medtronic Minimed, INC. | $67.71 | 2019 | |
| Medtronic, INC. | $59.96 | 2024-2025 | Minimed 780g |
| Astellas Pharma US INC | $50.24 | 2023-2024 | Veozah |
| Abbott Laboratories | $48.42 | 2020-2022 | |
| Mannkind Corporation | $42.50 | 2025 | |
| Ascendis Pharma Endocrinology INC | $42.25 | 2023-2024 | |
| Horizon Therapeutics Plc | $40.92 | 2023 | Tepezza |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $33.79 | 2019-2022 | |
| Beta Bionics, INC. | $32.54 | 2024 | Ilet Bionic Pancreas |
| Amneal Pharmaceuticals LLC | $32.51 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $23.54 | 2025 | Imcivree |
| Alexion Pharmaceuticals, INC. | $21.64 | 2024 | Strensiq |
| Pfizer INC. | $19.91 | 2022 | |
| Antares Pharma, INC. | $17.95 | 2024 | Xyosted |
| Acella Pharmaceuticals, LLC | $17.82 | 2024 | NP Thyroid 60 |
| Janssen Pharmaceuticals, INC | $16.33 | 2019 | |
| Ascensia Diabetes Care US INC. | $16.23 | 2024 | |
| Amgen INC. | $16.15 | 2024 | Tepezza |
| Qiagen, LLC | $13.91 | 2022 | |
| Avion Pharmaceuticals | $13.77 | 2023 | NP Thyroid 60 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.77 | 2022 | |
| Merck Sharp & Dohme LLC | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Escipion Pedroza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.